Background
Results
Generation of transformed human skin fibroblasts and human embryonic retinoblasts, including hMDMX as a potential oncogene
VH10 |
p21
|
hMDM2-p2
|
PUMA
| ||||||
---|---|---|---|---|---|---|---|---|---|
VH10 wt
| 1.00 | ± | 0.16 | 1.00 | ± | 0.17 | 1.00 | ± | 0.23 |
shp53
| 0.24 | ± | 0.03 | 0.20 | ± | 0.03 | 0.49 | ± | 0.11 |
HRasV12-shp53
| 0.15 | ± | 0.03 | 0.32 | ± | 0.07 | 0.44 | ± | 0.15 |
shRB-HRasV12-shp53
| 0.63 | ± | 0.11 | 0.41 | ± | 0.15 | 1.54 | ± | 0.32 |
HA-hMDMX
| 0.47 | ± | 0.09 | 0.61 | ± | 0.08 | 0.41 | ± | 0.08 |
HRasV12-HA-hMDMX
| 0.76 | ± | 0.12 | 1.05 | ± | 0.17 | 0.53 | ± | 0.14 |
shRB-HRasV12-HA-hMDMX
| 1.05 | ± | 0.12 | 1.14 | ± | 0.15 | 0.28 | ± | 0.07 |
HER
|
p21
|
hMDM2-p2
|
PUMA
| ||||||
HER wt
| 1.00 | ± | 0.16 | 1.00 | ± | 0.15 | 1.00 | ± | 0.19 |
shp53
| 0.11 | ± | 0.03 | 0.01 | ± | 0.01 | 0.46 | ± | 0.13 |
shRB-shp53
| 0.23 | ± | 0.05 | 0.02 | ± | 0.00 | 0.36 | ± | 0.06 |
shRB-HRasV12-shp53
| 0.05 | ± | 0.02 | 0.01 | ± | 0.00 | 0.15 | ± | 0.04 |
HA-hMDMX
| 1.51 | ± | 0.26 | 1.43 | ± | 0.28 | 0.67 | ± | 0.30 |
shRB-HA-hMDMX
| 1.01 | ± | 0.16 | 0.62 | ± | 0.13 | 0.34 | ± | 0.11 |
shRB-HRasV12-HA-hMDMX
| 2.52 | ± | 0.70 | 0.61 | ± | 0.17 | 0.60 | ± | 0.17 |
Cell line | Nutlin-3 treatment (h) | p53 | p21 | hMDM2 |
---|---|---|---|---|
0
| 1.00 | 1.00 | 1.00 | |
VH10 wt
|
6
| 4.96 | 6.68 | 82.32 |
24
| 7.82 | 11.16 | 149.60 | |
0
| 0.35 | 0.20 | 0.27 | |
shp53
|
6
| 0.87 | 0.65 | 0.30 |
24
| 1.25 | 2.26 | 4.54 | |
0
| 0.28 | 0.03 | 0.33 | |
HRasV12-shp53
|
6
| 0.30 | 0.09 | 0.78 |
24
| 0.44 | 0.33 | 0.74 | |
0
| 0.45 | 1.01 | 2.51 | |
shRB-HRasV12- shp53
|
6
| 0.49 | 1.24 | 4.55 |
24
| 0.74 | 2.85 | 9.17 | |
0
| 6.99 | 0.56 | 0.87 | |
HA-hMDMX
|
6
| 9.72 | 2.86 | 47.81 |
24
| 11.70 | 2.10 | 17.19 | |
0
| 1.63 | 0.63 | 0.69 | |
HRasV12-HA-hMDMX
|
6
| 4.13 | 2.88 | 36.75 |
24
| 5.01 | 3.07 | 29.42 | |
0
| 1.07 | 1.45 | 2.79 | |
shRB-HRasV12-HA-hMDMX
|
6
| 2.38 | 5.37 | 132.80 |
24
| 1.76 | 4.28 | 79.91 |
Alterations in morphology and proliferation rate during transformation process
Effect of hMDMX overexpression on anchorage-independent growth
Role of hMDMX in tumorigenicity in vivo
hMDMX overexpression inhibits the Nutlin-3 induced p53 response in VH10 skin fibroblasts
Cell line | Nutlin-3 treatm (h) |
p53
|
p21
|
hMDM2
|
hMDM2-p2
|
hMDMX
|
PUMA
|
GADD45a
|
SURVIVIN
| ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
VH10 wt
|
0
| 1.00 | ± | 0.19 | 1.00 | ± | 0.16 | 1.00 | ± | 0.16 | 1.00 | ± | 0.17 | 1.00 | ± | 0.16 | 1.00 | ± | 0.23 | 1.00 | ± | 0.38 | 1.00 | ± | 0.16 |
6
| 1.10 | ± | 0.18 | 9.36 | ± | 1.34 | 28.62 | ± | 5.40 | 43.93 | ± | 6.93 | 1.38 | ± | 0.21 | 4.90 | ± | 1.06 | 5.17 | ± | 1.45 | 0.90 | ± | 0.14 | |
24
| 0.79 | ± | 0.18 | 11.98 | ± | 2.09 | 26.42 | ± | 5.42 | 66.60 | ± | 11.19 | 0.95 | ± | 0.16 | 4.49 | ± | 1.25 | 4.89 | ± | 1.79 | 0.02 | ± | 0.00 | |
shp53
|
0
| 1.00 | ± | 0.09 | 1.00 | ± | 0.11 | 1.00 | ± | 0.25 | 1.00 | ± | 0.09 | 1.00 | ± | 0.09 | 1.00 | ± | 0.23 | 1.00 | ± | 0.11 | 1.00 | ± | 0.13 |
6
| 0.85 | ± | 0.17 | 2.24 | ± | 0.24 | 1.56 | ± | 0.31 | 4.26 | ± | 0.43 | 0.91 | ± | 0.17 | 1.84 | ± | 0.35 | 1.46 | ± | 0.28 | 1.18 | ± | 0.14 | |
24
| 0.63 | ± | 0.54 | 5.36 | ± | 0.45 | 4.08 | ± | 0.92 | 9.46 | ± | 0.73 | 1.00 | ± | 0.12 | 3.29 | ± | 0.54 | 1.28 | ± | 0.12 | 0.85 | ± | 0.11 | |
HRasV12-shp53
|
0
| 1.00 | ± | 0.35 | 1.00 | ± | 0.27 | 1.00 | ± | 0.32 | 1.00 | ± | 0.28 | 1.00 | ± | 0.29 | 1.00 | ± | 0.41 | 1.00 | ± | 0.28 | 1.00 | ± | 0.23 |
6
| 0.81 | ± | 0.24 | 1.34 | ± | 0.33 | 1.29 | ± | 0.39 | 1.97 | ± | 0.56 | 1.09 | ± | 0.41 | 1.19 | ± | 0.40 | 1.14 | ± | 0.30 | 0.99 | ± | 0.22 | |
24
| 0.84 | ± | 0.28 | 2.11 | ± | 0.50 | 1.44 | ± | 0.36 | 2.37 | ± | 0.66 | 1.18 | ± | 0.30 | 1.53 | ± | 0.47 | 1.37 | ± | 0.32 | 1.06 | ± | 0.22 | |
shRB-HRasV12-shp53
|
0
| 1.00 | ± | 0.24 | 1.00 | ± | 0.18 | 1.00 | ± | 0.22 | 1.00 | ± | 0.48 | 1.00 | ± | 0.19 | 1.00 | ± | 0.18 | 1.00 | ± | 0.18 | 1.00 | ± | 0.18 |
6
| 0.88 | ± | 0.24 | 1.54 | ± | 0.30 | 1.16 | ± | 0.30 | 2.61 | ± | 0.97 | 1.22 | ± | 0.24 | 1.22 | ± | 0.54 | 1.49 | ± | 0.63 | 1.00 | ± | 0.20 | |
24
| 0.98 | ± | 0.27 | 2.49 | ± | 0.67 | 1.68 | ± | 0.66 | 6.32 | ± | 2.59 | 1.18 | ± | 0.38 | 1.35 | ± | 0.35 | 1.76 | ± | 0.48 | 0.59 | ± | 0.16 | |
HA-hMDMX
|
0
| 1.00 | ± | 0.17 | 1.00 | ± | 0.22 | 1.00 | ± | 0.03 | 1.00 | ± | 0.08 | 1.00 | ± | 0.34 | 1.00 | ± | 0.14 | 1.00 | ± | 0.09 | 1.00 | ± | 0.58 |
6
| 0.74 | ± | 0.23 | 4.14 | ± | 0.67 | 3.47 | ± | 1.26 | 11.83 | ± | 1.00 | 1.42 | ± | 0.36 | 3.05 | ± | 0.49 | 1.25 | ± | 0.58 | 1.52 | ± | 0.64 | |
24
| 1.63 | ± | 0.25 | 6.86 | ± | 1.71 | 11.92 | ± | 1.36 | 18.14 | ± | 2.03 | 1.80 | ± | 0.58 | 5.45 | ± | 1.00 | 2.88 | ± | 0.93 | 0.48 | ± | 0.20 | |
HRasV12-HA-hMDMX
|
0
| 1.00 | ± | 0.14 | 1.00 | ± | 0.16 | 1.00 | ± | 0.16 | 1.00 | ± | 0.16 | 1.00 | ± | 0.22 | 1.00 | ± | 0.29 | 1.00 | ± | 0.14 | 1.00 | ± | 0.16 |
6
| 0.90 | ± | 0.16 | 6.78 | ± | 1.16 | 9.01 | ± | 1.83 | 17.33 | ± | 2.97 | 1.09 | ± | 0.22 | 3.09 | ± | 0.91 | 1.27 | ± | 0.21 | 0.79 | ± | 0.22 | |
24
| 0.79 | ± | 0.10 | 10.38 | ± | 2.76 | 12.08 | ± | 1.58 | 26.21 | ± | 2.95 | 0.74 | ± | 0.11 | 3.50 | ± | 0.85 | 1.69 | ± | 0.19 | 0.26 | ± | 0.03 | |
shRb-HRasV12-HA-hMDMX
|
0
| 1.00 | ± | 0.10 | 1.00 | ± | 0.05 | 1.00 | ± | 0.09 | 1.00 | ± | 0.07 | 1.00 | ± | 0.05 | 1.00 | ± | 0.26 | 1.00 | ± | 0.05 | 1.00 | ± | 0.06 |
6
| 1.04 | ± | 0.13 | 4.57 | ± | 0.46 | 6.46 | ± | 1.61 | 13.53 | ± | 2.08 | 1.01 | ± | 0.13 | 3.10 | ± | 0.63 | 1.73 | ± | 0.26 | 0.81 | ± | 0.13 | |
24
| 0.99 | ± | 0.14 | 5.76 | ± | 0.92 | 6.55 | ± | 0.94 | 15.36 | ± | 2.04 | 0.96 | ± | 0.14 | 5.33 | ± | 1.27 | 1.71 | ± | 0.28 | 0.23 | ± | 0.03 |
hMDMX overexpression in HER cells is not sufficient to inhibit the Nutlin-3 induced p53 response
Discussion
Conclusions
Methods
Generation of stably transformed human cell lines
Immunoblotting
Protein | Name/cat. # | Company |
---|---|---|
hMDMX | A300-287A | Bethyl Laboratories, Montgomery TX, USA |
hMDMX | 6B1A | [50] |
HA-tag | HA.11 | Covance, Princeton, New Jersey, USA |
HA-tag | ab9110 | Abcam, Cambridge, UK |
p53° | DO-1/sc-126 | Santa Cruz Biotechnology, Santa Cruz, CA, USA |
p53° | PAb 1801/sc-98 | Santa Cruz Biotechnology, Santa Cruz, CA, USA |
p53 | FL-393 | Santa Cruz Biotechnology, Santa Cruz, CA, USA |
hMDM2 */MDM2 | 4B2 | [51] |
hMDM 2 * | SMP14 sc-6965 | Santa Cruz Biotechnology, Santa Cruz, CA, USA |
p21 | CP74/05-655 | Upstate Biotechnology, Lake Placid, NY, USA |
RB | G3-245/554136 | BD Pharmingen, Franklin Lakes, New Jersey, USA |
HRas | Y13-259 | [52] |
HAUSP/USP7 | A300-033A | Bethyl Laboratories, Montgomery TX, USA |
HAUSP/USP7 | 7G9 | [53] |
p21 | CP74/05-655 | Upstate Biotechnology, Lake Placid, NY, USA |
γ-tubulin | GTU-88/T6557 | Sigma-Aldrich, St Louis, MO, USA |
Immunofluorescence
RNA isolation, qRT-PCR
hMDM2-P2 Fw | 5'-acgcacgccactttttctct- 3' |
hMDM2-P2 Rv | 5'-tccgaagctggaatctgtgag- 3' |
P53 Fw | 5'-ctctccccagccaaagaagaa- 3' |
P53 Rv | 5'-tccaaggcctcattcagctct- 3' |
hMDMX Fw | 5'-aggtgcgcaaggtgaaatgt- 3' |
hMDMX Rv | 5'-ccatatgctgctcctgctgat- 3' |
PUMA Fw | 5'-gacctcaacgcacagta- 3' |
PUMA Rv | 5'-ctaattgggctccatct- 3' |
p21 Fw | 5'-agcagaggaagaccatgtgga- 3' |
p21 Rv | 5'-aatctgtcatgctggtctgcc- 3' |
SURVIVIN Fw | 5'-gagacagaatagagtgatagg- 3' |
SURVIVIN Rv | 5'-gacagatgtgaaggttgg- 3' |
GADD45A Fw | 5'-gcgacctgcagtttgcaata- 3' |
GADD45A Rv | 5'-atcccccaccttatccatcct- 3' |
CAPNS1 Fw | 5'-atggttttggcattgacacatg- 3' |
CAPNS1 Rv | 5'-gcttgcctgtggtgtcgc- 3' |
TBP Fw | 5'-cacgaaccacggcactgatt- 3' |
TBP Rv | 5'-ttttcttgctgccagtctggac- 3' |
RPS11 Fw | 5'-aagcagccgaccatctttca- 3' |
RPS11 Rv | 5'-cgggagcttctccttgcc- 3' |
SRPR Fw | 5'-cattgcttttgcacgtaaccaa- 3' |
SRPR Rv | 5'-attgtcttgcatgcggcc- 3' |
CDC25A Fw | 5'-ctccgagtcaacagattcagg- 3' |
CDC25A Rv | 5'-ttcaaggttttctttactgtccaa- 3' |